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Abstract
In order to quantify the association between use of statins and the risk of all
hematological malignancies and of subtypes, we performed a meta-analysis of
observational studies. We achieved a MEDLINE/EMBASE comprehensive search
for studies published up to August 2014 investigating the association between use
of statins and the risk of hematological malignancies, including Hodgkin- and
non-Hodgkin lymphoma, leukemia, and myeloma. Fixed- and random-effect
models were fitted to estimate the summary relative risk (RR) based on adjusted
study-specific results. Between-study heterogeneity was assessed using the Q and
I2 statistics and the sources of heterogeneity were investigated using Deeks’ test.
Moreover, an influence analysis was performed. Finally, publication bias was eval-
uated using funnel plot and Egger’s regression asymmetry test. Fourteen studies
(10 case–control and four cohort studies) contributed to the analysis. Statin use,
compared to nonuse of statins, was negatively associated with all hematological
malignancies taken together (summary RR 0.86; 95% CI: 0.77–0.96), with leuke-
mia (0.83; 0.74–0.92), and non-Hodgkin lymphoma (0.81; 0.68 to 0.96), but it
was not related to the risk of myeloma (0.89; 0.53–1.51). Long-term users of sta-
tins showed a statistically significant reduction in the risk of all hematological
malignancies taken together (0.78; 0.71–0.87). Statistically significant between-
studies heterogeneity was observed for all outcome except for leukemia. Heteroge-
neity was caused by differences confounding-adjustment level of the included
studies only for Myeloma. No significant evidence of publication bias was found.
Introduction
Statins (HMG-CoA-reductase inhibitors) are the most
commonly prescribed drugs worldwide to reduce plasma
cholesterol levels due to their cardiovascular protective
effects and excellent tolerability [1–4] and their use has
increased strikingly in the past decade [5]. Recent in vivo
investigations have suggested that these drugs may have a
chemopreventive potential against hematopoietic and
lymphatic malignancies [6–8]. A study on humans
showed a protective effect on non-Hodgkin lymphoma in
subjects affected by the genetic deficiency of glucose-
6-phosphate dehydrogenase leading to the reduced
availability of the NADPH, required for the activity of
3-hydroxy-3-methylglutaryl CoA reductase [9]. Some
observational studies reported decreased non-Hodgkin
lymphoma risk of 26–45% in users of statins [10, 11]. A
protective effect on the risk of hematological malignan-
cies of the same strength (24%) was reported for long-
term use of statins versus short-term use of statins [12].
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Moreover, a reduction in the multiple myeloma risk of
60% [13] and in the leukemia risk of 26% [14] for any
use of statins was showed. However, inconsistent findings
were retrieved from meta-analytic approach. A meta-
analysis, based on six randomized trials and eight
observational studies, did not support a potential role of
statins in the prevention of any hematological malignan-
cies [15] while a recent meta-analysis, based on 14
observational studies, showed chemopreventive effects
against hematological malignancies [16]. Moreover, to
our knowledge only a relatively dated meta-analysis had
evaluated the effect of statins on the risk of specific
hematological cancer. This meta-analysis considered a few
studies for specific hematological malignancies and
showed a protective effect only for lymphoma (median
relative risk [RR] 0.74, range 0.28–2.2) [17].
Thus, the effect of statins on the risk of all and subtype
hematological malignancies remains to be determined. To
address this issue, we carried out a meta-analysis of avail-
able observational studies published on this topic.
Methods
Search strategy and study selection
We carried out a MEDLINE and EMBASE search for
observational studies published up to August 2014 which
investigated the association between “statin” and risk of
“hematological malignancies.”
The following keywords and/or corresponding MeSH
terms were used: (“Hydroxymethylglutaryl-CoA reductase
inhibitors” OR “HMG-CoA-reductase inhibitors” OR “sta-
tin” OR “simvastatin” OR “pitavastatin” OR “lovastatin”
OR “fluvastatin” OR “pravastatin” OR “atorvastatin” OR
“rosuvastatin”) AND (“hematologic malignancies” OR
“hematologic neoplasms” OR “hematopoietic malignan-
cies” OR “hematopoietic neoplasms” OR “lymphoma” OR
“leukemia” OR “myeloma”). In addition, the reference lists
of reviews and meta-analyses published on this issue, iden-
tified in MEDLINE and Cochrane Library, were hand-
checked to find additional relevant publications [15–23].
All identified titles and abstracts were accurately
scanned to exclude studies that did not fit inclusion cri-
teria. Cohort and case–control studies were both
included, provided that they (1) investigated any use of
statin and that explicitly considered nonusers of statins
as the reference category; (2) considered as outcome of
the following events: hematological malignancy as a
whole and/or specific malignancies such as Hodgkin-
and non-Hodgkin lymphoma, leukemia, and myeloma;
(3) reported crude or adjusted estimates of the associa-
tion between exposure and outcome (odds ratio [OR],
or hazard ratio [HR] considered as RRs [24] and their
corresponding 95% CI or P-value) or sufficient data to
calculate them.
When data were published more than once, the most
recent and complete publication was considered. Two
readers (D. P. and D. S.), independently determined the
eligibility of each article for inclusion. Discrepancies
between readers were resolved in conference.
Data collection
The following data were collected from each included
article: publication year, study design, country, source of
data, characteristics of the subjects (e.g., gender), number
of cases, cancer type, control for confounding factors
(matching or adjustments), and estimates for exposure–
outcome relationship together with corresponding 95%
confidence interval (CI) or P-value.
Statistical analysis
The summary RR for use of statin versus no use (includ-
ing never use and short duration of statin use) and risk
of all and subtype hematological malignancies was the
main measure of interest. Analyses were performed for
hematological malignancies as a whole, as well as for each
subtype, provided that the corresponding estimates were
available in at least three studies. Where possible, we
included in the analysis the adjusted estimates of the RR
from the original studies; otherwise we used raw data and
computed unadjusted RRs.
The dose–response analysis was performed only for
articles where the association estimates for “long-term
users” considered a treatment period longer than 4 years
versus no users.
Between-study heterogeneity was tested by Cochran’s Q
test [25] and measured with the I2 statistics (the proportion
of between-study variability caused by heterogeneity) [26].
We pooled the original estimates by using both the Mantel
& Haenszel method (fixed-effects model) and the DerSimo-
nian & Laird method (random-effects model) [27]. When a
significant heterogeneity was found, the results from the
random-effects model were showed. Between-study sources
of heterogeneity were investigated by stratifying original
estimates according to some study characteristics poten-
tially relevant in causing heterogeneity, that is, study design
(cohort or case–control), geographic area (Europe, Other
countries), level of control for possible confounders (low:
only sociodemographic characteristics; high: sociodemo-
graphic and other variables or no adjusted). The Deeks test
was used to evaluate the significancy of the difference
between subgroups [27]. An influence analysis was also
conducted by omitting one study at a time, in order to
identify to what extent the results were influenced by a sin-
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gle study. Publication bias was evaluated through funnel
plot visual analysis and the Egger’s test [28].
All tests were considered statistically significant for
P-values less than 0.05. The analyses and the corresponding
graphical visualization of forest and funnel plots were,
respectively, conducting using Review Manager (RevMan
5.1) (Nordic Cochrane Center) and STATA Software Pro-
gram Version 9 (STATA, College Station, TX). The PRIS-
MA statements were taken into account in this paper [29].
Results
Figure 1 shows the flow diagram for study inclusion.
Based on title and abstract the PUBMED search allowed
to identify 273 papers, further 165 papers were retrieved
by EMBASE search. After the duplicate removal, we con-
sidered 310 studies. We excluded 282 papers because they
were unrelated to the issue and further 14 papers because
they did not satisfy the inclusion criteria. The remaining
14 studies [10–14, 30–38] were considered for meta-
analysis. Table 1 shows that these comprised four cohort
and 10 case–control studies on a total of 17,886 patients
with hematological malignancies (irrespectively from their
subtype), of which 1174 with leukemia (five studies; for
one study [14] the number of cases was not available),
3469 with non-Hodgkin lymphoma (seven studies), and
609 myelomas (four studies).
Figure 2 shows the study-specific and summary RR for
use versus nonuse of statins. The summary RR for all
hematological malignancies irrespectively from their
subtype was 0.86 (95% CI: 0.77–0.96) without statistically
significant difference (Deeks test P-value 0.64) between
cohort (summary RR, 0.89; 95% CI: 0.82–0.95) and case–
control (summary RR, 0.83; 95% CI: 0.62–1.09) studies.
There was no statistically significant association (the
corresponding summary RR, and 95% CI, being 0.89,
0.53–1.51) for myeloma, but there was a significant
between-study heterogeneity (Chi2 test P-value and I2 sta-
tistics being 0.0002 and 81%).
A statistically significant reduction in the risk was
observed for both, leukemia (summary RR 0.83; 95% CI:
0.74–0.92), and non-Hodgkin lymphoma (summary RR
0.81; 95% CI: 0.68–0.96) with a statistically significant
between-study heterogeneity only for the latter one (Chi2
test P-value and I2 statistics, respectively, of 0.005 and
61% for non-Hodgkin lymphoma and of 0.220 and 25%
for leukemia).
In the stratified analysis performed to identify the
sources of heterogeneity, only the different level of con-
trol for possible confounders showed evidence of modify-
ing the summary analysis of Myeloma (P-value 0.0002).
These results were partially influenced by omitting one
study at a time. A statistically nonsignificant reduction in
the risk of non-Hodgkin lymphoma was observed in statin
Papers identified through 
PUBMED search and screened by 
title and abstratct:
273
Papers identified through EMBASE 
search and screened by title and
abstratct:
165
Number of articles after duplicates removed:
310
Full text studies examined for 
evaluating inclusion criteria:
28
The study was unrelated 
the issue according to 
title and/or abstract:
282
The study did not 
investigate HM risk in 
human:
13
The study was a meta-
analysis:
1
Papers included in the meta-
analysis on treatment with statin 
and incident cancer risk:
14
Figure 1. Flowchart of the selection of studies for inclusion in the meta-analysis.
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Figure 2. Study-specific and summary relative risk estimates for the association between use of statins and the risk of all hematological
malignancies taken together, leukemia, myeloma, and non-Hodgkin lymphoma. Squares represent study-specific relative risk estimates (size of the
square reflects the study-specific statistical weight, i.e., the inverse of the variance); horizontal lines represent 95% CIs; diamonds represent
summary relative risk estimates with corresponding 95% CIs; P-values are from testing for heterogeneity across study-specific estimates.
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users omitting the studies of Fortuny et al. [36] or of
Jacobs et al. [10] with new summary RRs, respectively, of
0.84 (95% CI: 0.70–1.02) and 0.80 (95% CI: 0.64–1.01).
Analogously, for leukemia, the exclusion of Vinogradova
et al. study [14] nullified the association with a new sum-
mary RR of 0.90 (95% CI: 0.77 to 1.05). Finally, for mye-
loma the omission of the study of Fortuny et al. [36] or
of Landgren et al. [13] nullified the potential protective
effect of statins with new summary RRs estimates, respec-
tively, of 1.02 (95% CI: 0.57–1.83) and 1.06 (95% CI:
0.61–1.84).
Since influence effects were observed for both hospital
(Fortuny et al. [36]) and/or population-based design
(Jacobs et al. [10], Vinogradova et al. [14], Landgren
et al. [13]) we think that our estimates are light affected
by source of data of included studies. Moreover, the Iwata
study showed the more elevated risk but its influence was
limited (weight 4-16%).
Figure 3 shows the study-specific and summary RR of
all hematological malignancies associated with “long-term
use” of statins. A statistically significant reduction in the
risk was observed with a summary RR of 0.78, 95% CI:
0.71–0.87, without any evidence of between-study hetero-
geneity (Chi2 test P-value 0.270 and I2 = 18%).
There was some evidence of publication bias from visu-
alization of the funnel plot (Fig. 4), but this was not con-
firmed from corresponding Egger’s test (hematological
malignancies P-value = 0.453, leukemia P-value = 0.120,
myeloma P-value = 0.983, and non-Hodgkin lymphoma
P-value = 0.904.
Discussion
We analyzed the data from 14 observational studies in
order to evaluate the effect of statins on the risk of both
all and subtype hematological malignancies. Our compre-
hensive meta-analysis showed a statistically significant
reduction in the risk of hematological malignancies
according to the meta-analytic results of Yi et al. [16].
Moreover, in our study a statistically significant risk
reduction from summarizing estimates associated with
“long-term use” of statins was observed scoring in favor
of the hypothesis of a causal association between chronic
use of statins and hematological malignancies.
Two relevant studies: (1) a study of six randomized
clinical trials eight observational studies; (2) a pooled
individual-level data of 27 randomized trials that did
not show any effect of statin therapy on the risk of all
hematological malignancies [16, 39]. The inconsistency
of this findings with our results could be caused by the
small number of observational studies included (only
eight studies) and by the fact that randomized controlled
trials may not be appropriate for the assessment of rare
outcomes or effects that take a long time to develop, in
fact total number of hematological malignancies in all
27 eligible RCTs was 614, compared to 17,866 in the
current meta-analysis of observational studies [40].
Analyzing specific subtype hematological malignancies
we observed a potential protective effect for leukemia
(summary RR 0.83; 95% CI: 0.74–0.92) and non-Hodgkin
lymphoma (summary RR 0.81; 95% CI: 0.68–0.96),
Figure 3. Study-specific and summary relative risk estimates for the association between “long-term” use of statins and the risk of hematological
malignancies. Squares represent study-specific relative risk estimates (size of the square reflects the study-specific statistical weight, i.e., the
inverse of the variance); horizontal lines represent 95% CIs; diamonds represent summary relative risk estimates with corresponding 95% CIs;
P-values are from testing for heterogeneity across study-specific estimates.
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although the high between-studies heterogeneity for the
latter outcome suggests that the findings should still be
regarded as inconclusive.
Our results are consistent with several previous find-
ings. Two in vitro studies showed that statins suppress
the growth of promyelocytic and lymphocytic leukemic
cells [41, 42]. One study conducted on 28 inbred rats
showed that treatment with Lovastatin caused inhibition
of spontaneous metastasis of poorly differentiated lym-
phomas without affecting primary tumor growth [6].
Experimental cancer models have shown that Lovastatin
induces a profound apoptotic response in cells derived
from juvenile monomyelocytic leukemia. Tumor cells
themselves differ significantly in their sensitivity to statin-
induced cell death: myeloblastic leukemia cells and
neuroblastoma cells seem to be particularly sensitive to
statin-induced apoptosis, whereas acute lymphoblastic
leukemia cells are relatively insensitive [43].
The strength of the evidence for the effect of statins use
on leukemia is reduced by the observation that the result
was modified by the omission of the most relevant study
on this issue (summary RR 0.90 [95% CI: 0.77–1.05])
[14]. However, if the selective inclusion with protective
effect of statins on the risk of leukemia, suggested by fun-
nel plot, were real our association measurements could be
underestimated. Moreover, selective exclusion of the so-
called “grey literature” (PhD theses, abstracts, conference
proceedings, etc.) might also play a role. Nevertheless, the
results that statins may exert a protective effect on the
risk of leukemia call for a greater attention to this impor-
tant issue in future studies.
Finally, no evidence of protective effect of statins use
on myeloma was reported (summary RR 0.89, 95% CI:
0.53–1.51) perhaps due to the small number of studies
and the high between-studies heterogeneity.
Our results have limitations which mainly reflect the
sources of bias of the observational studies included into
the meta-analysis. In particular, observational investiga-
tions lacked random allocation of the intervention neces-
sary to correctly investigate exposure–outcome causal
(A) (B)
(D)(C)
Figure 4. Funnel plot for publication bias of studies investigating the association between use of statins and the risk of all hematological
malignancies taken together (A), leukemia (B), myeloma (C), and non-Hodgkin lymphoma (D).
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relationship. As a result, we cannot exclude the possibility
that confounding by indication might explain our findings.
Despite primary studies reported estimates adjusted for the
history of several medical conditions associated with statin
use that might also affect hematological malignancies risk,
residual confounding remains a potential limitation.
Furthermore, since little is known about the etiology of
hematological malignancies, we cannot rule out unknown
confounders as possible explanation for our findings. The
definition of outcome varied from study to study. Com-
bining studies would increase the power for a given
hematological malignancy subtype, but the heterogeneity
would also have increased. Further, cholesterol levels
influence statin use as well as possibly modifying cancer
risk, though data are inconsistent [44]. The decreased risk
of hematological malignancies could be explained by
reverse causality, as patients with such diagnoses are more
likely to have lower lipid levels [45]. Another limitation
was the inability to evaluate the effect of various types of
statins, given the considerable variation in their bioavail-
ability [46].
Conclusion
Given the widespread and rapidly increasing use of sta-
tins, any association with an increased or decreased risk
of no cardiovascular disease would have substantial pub-
lic health impact. Our study provides evidence that sta-
tins seem to reduce the risk of hematological
malignancy. We also found that statins users had a sta-
tistically significant reduced risk of leukemia and non-
Hodgkin lymphoma than nonusers. Moreover, evidence
on long-term effects of statins on hematological malig-
nancies is available. These evidences, although not con-
clusive because based on a small number of studies
included in this meta-analysis and characterized by a
strong heterogeneity among study-specific association
estimates are interesting signals on a secondary potential
benefit of statins therapy.
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